Bank Julius Baer & Co’s Ascendis Pharma A/S ASND Stock Holding History

Bank Julius Baer & Co’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-195	Closed	-$26K	–	599
2021 Q4	$26K	Hold	195	–	–	﹤0.01%	719
2021 Q3	$31K	Buy	195 +66	+51%	+$9.03K	﹤0.01%	720
2021 Q2	$17K	Buy	+129	New	+$17.2K	﹤0.01%	762

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank Julius Baer & Co's ASND Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Ascendis Pharma A/S (ASND) in Q1 2022, closing a stake of 195 shares — an estimated $26K sold.

Bank Julius Baer & Co first reported a position in ASND in Q2 2021 and held it in 3 quarters. The position peaked at $31K in Q3 2021. 178 funds tracked by Wall St. Rank hold ASND as of Q1 2022.

Bank Julius Baer & Co reported no remaining Ascendis Pharma A/S position as of Q1 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 195 Ascendis Pharma A/S shares in Q1 2022, an estimated $26K.
Bank Julius Baer & Co first reported a position in Ascendis Pharma A/S in Q2 2021 and held it in 3 quarters.
Bank Julius Baer & Co's Ascendis Pharma A/S position peaked at $31K in Q3 2021.
178 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.